
Psiconáutica Editorial Team · November 17, 2026
At a glance
- What it is: the protocol for an Emory University study on difficulties that persist after a psychedelic experience or after meditating, posted as a preprint on medRxiv.
- What it will do: survey 1,600 affected people, follow 800 for a year and interview 60 in depth. The aim is to describe types of problems, how they evolve and which supports help.
- What it cannot say: how often these difficulties occur among people who use psychedelics or meditate, or whether one practice is riskier than the other.
Most psychedelic studies look at effects during the session or benefits weeks later. Much less is known about people who, once the acute effects have passed, continue to experience anxiety, perceptual changes, disconnection or problems functioning in daily life. A team coordinated from Emory University in Atlanta, with researchers from Brown, the University of Melbourne and other institutions, has published the protocol for a study designed to describe these experiences in more detail. It is a work plan: it contains no data or clinical conclusions and, as a preprint, it has not been peer reviewed. The first version appeared on October 29; the second, dated November 4, only corrects the typeface on a few pages.
What the study proposes
The design combines four parts. A retrospective survey will gather 1,600 people in two groups of 800: one with difficulties attributed to psychedelics and one with difficulties attributed to meditation, which serves as the comparator. Of these, 800 (400 per group) will take part in a 12-month follow-up with six questionnaires, one every two months. Forty people will also keep a weekly diary for 12 weeks, with symptom ratings and audio-recorded accounts. Sixty will be interviewed.
The team has built a pool of 270 questions, spread across 59 categories and seven domains, based on earlier research and input from people with lived experience. It will be complemented by an adapted version of WHODAS 2.0, a World Health Organization questionnaire on limitations in daily life. There will also be questions about the substance, prior mindset (set), environment (setting), social support and the remedies tried.
Who can take part
Participants are people who attribute to a psychedelic or to meditation a difficulty that persisted after the acute effects, or beyond a single session. That difficulty must have caused distress, affected their functioning or required additional support. The psychedelic group covers psilocybin, LSD, DMT, ayahuasca, 5-MeO-DMT and mescaline, as well as MDMA, ibogaine and ketamine; cannabis is excluded. The aim is for half of each group to have problems that began in the past year and that have not improved by more than 70%. The study website asks participants to be 18 or older, read English and live in the United States, Canada or Australia. Recruitment channels include sites that run clinical trials, community organizations and clients of Oregon’s licensed psilocybin services.
Where it stands
According to the protocol, by October 2026 about 200 surveys had been completed in the psychedelic group and about 60 in the meditation group, out of 800 planned in each, along with nine interviews. No analyses had been run. The study is funded by an anonymous gift and, according to the authors, the donor plays no part in the analysis. Several authors declare ties to industry or to support organizations such as Cheetah House, which helps people who have had difficult meditation experiences.
Why it will not measure how often this happens
The sample is enriched: people with difficulties are sought out deliberately. The authors acknowledge that this limits inferences about prevalence and that participants do not represent users or meditators as a whole. The observational design also does not allow causes to be inferred or differences between groups to be attributed to the action of a substance, and the comparison with meditation will be descriptive. In addition, everything depends on self-report, with possible recall bias. The team itself expects those with the greatest impairment to drop out sooner, which could make the course of these problems look more benign than it is.
What it means
For harm reduction, the value lies in vocabulary and tools. Knowing what forms these difficulties take, how long they last and what helps can guide support services and professionals. It complements recent work such as the Yale study on lingering visual changes. Anyone going through something similar can consult our harm-reduction guide and seek professional help. The data will be needed before knowing what the study contributes.
Sources
- Lipson J, Canby N, Salako Z, et al. Post-psychedelic and meditation-related challenges: a protocol for a mixed-methods longitudinal-observational study. medRxiv, version 2, November 4, 2026 (version 1: October 29, 2026). DOI: 10.64898/2026.10.26.26366468. Preprint, not peer reviewed.
- Emory University. Post-Psychedelic Challenges Study, study website.
Image: front of the Emory University School of Medicine in Atlanta, the institution coordinating the study. Photo: Countzander, Wikimedia Commons, dedicated to the public domain under CC0 1.0.
Educational content produced from a harm-reduction perspective and with respect for individual freedom. It does not replace information from a healthcare professional and does not aim to encourage or condemn any use.